Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape

Uliano, Jacopo; Nicolò, Eleonora; Corvaja, Carla; Salimbeni, Beatrice Taurelli; Trapani, Dario; Curigliano, Giuseppe

doi:10.1080/17512433.2022.2142559

Cited by 4 publications

(2 citation statements)

References 118 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Remarkable progress has been made in recent years in the treatment of urogenital tumors by using the combination of ADCs and ICIs [ 13 ]. ADCs and ICIs possess complementary mechanisms of action that provide different therapeutic effects [ 14 ]. As shown in Fig.…”

Section: Introductionmentioning

confidence: 99%

The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies

Yu,

Zhu,

You

et al. 2024

Cell Death Dis

View full text Add to dashboard Cite

With the high incidence of urogenital tumors worldwide, urinary system tumors are among the top 10 most common tumors in men, with prostate cancer ranking first and bladder cancer fourth. Patients with resistant urogenital tumors often have poor prognosis. In recent years, researchers have discovered numerous specific cancer antigens, which has led to the development of several new anti-cancer drugs. Using protein analysis techniques, researchers developed immune checkpoint inhibitors (ICIs) and antibody-conjugated drugs (ADCs) for the treatment of advanced urogenital tumors. However, tumor resistance often leads to the failure of monotherapy. Therefore, clinical trials of the combination of ICIs and ADCs have been carried out in numerous centers around the world. This article reviewed phase 2 and 3 clinical studies of ICIs, ADCs, and their combination in the treatment of urogenital tumors to highlight safe and effective methods for selecting individualized therapeutic strategies for patients. ICIs activate the immune system, whereas ADCs link monoclonal antibodies to toxins, which can achieve a synergistic effect when the two drugs are combined. This synergistic effect provides multiple advantages for the treatment of urogenital tumors.

show abstract

Section: Introductionmentioning

confidence: 99%

The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies

Yu,

Zhu,

You

et al. 2024

Cell Death Dis

View full text Add to dashboard Cite

show abstract

“…Pembrolizumab is administered intravenously every two weeks in a phase II clinical trial to two cohorts of patients with metastatic TNBC: (A) an unselected population of advanced patients, and (B) a first-line cohort of PD-L1-positive tumors. The 170 patients in cohort A had a median OS of 9.0 months, a median PFS of 2.0 months, and an ORR of 5.7% for PD-L1 positive patients [ 77 ]. The median PFS, median OS, and ORR for the 84 patients in group B were 2.1 months, 18.0 months, and 21.4%, respectively [ 78 ].…”

Section: Introductionmentioning

confidence: 99%

Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired

et al. 2023

View full text Add to dashboard Cite

Cancer is still the leading cause of death globally. The approval of the therapeutic use of monoclonal antibodies against immune checkpoint molecules, notably those that target the proteins PD-1 and PD-L1, has changed the landscape of cancer treatment. In particular, first-line PD-1/PD-L1 inhibitor drugs are increasingly common for the treatment of metastatic cancer, significantly prolonging patient survival. Despite the benefits brought by immune checkpoint inhibitors (ICIs)-based therapy, the majority of patients had their diseases worsen following a promising initial response. To increase the effectiveness of ICIs and advance our understanding of the mechanisms causing cancer resistance, it is crucial to find new, effective, and tolerable combination treatments. In this article, we addressed the potential of ICIs for the treatment of solid tumors and offer some insight into the molecular pathways behind therapeutic resistance to ICIs. We also discuss cutting-edge therapeutic methods for reactivating T-cell responsiveness after resistance has been established.

show abstract

Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities

Matossian

Chen

Nanda

2023

Curr Breast Cancer Rep

View full text Add to dashboard Cite

Purpose of Review Triple-negative breast cancer (TNBC) is notoriously difficult to treat. Recent technological advances have led to the identification of novel targets and new approaches to treat this devastating disease. The aim of this review is to highlight therapeutic vulnerabilities of TNBC and discuss novel therapeutic strategies. Recent Findings Interrogating the inherent heterogeneity and rich cellular and transcriptional diversity within TNBC has led to the discovery of vulnerabilities and actionable targets for therapeutic development. Characterization of the tumor immune environment, discovery of novel molecular targets, and identification of somatic alterations which confer sensitivity to DNA repair inhibitors are just a few examples. Summary The key to developing effective strategies to treat TNBC is to exploit vulnerabilities using a multifaceted approach. The identification of actionable targets has led to numerous therapeutic advances for TNBC, resulting in substantial improvements in patient outcomes and quality of life.

show abstract

Combination immunotherapy strategies for triple-negative breast cancer: current progress and barriers within the pharmacological landscape

Cited by 4 publications

References 118 publications

The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies

The combination of immune checkpoint inhibitors and antibody-drug conjugates in the treatment of urogenital tumors: a review insights from phase 2 and 3 studies

Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired

Exploiting Therapeutic Vulnerabilities in Triple-Negative Breast Cancer: Successes, Challenges, and Opportunities

Contact Info

Product

Resources

About